Le Lézard
Classified in: Health
Subjects: NPT, CHI, PSF, CFG, DEI

Government of Canada announces partnership with the Canadian Academy of Health Sciences to assess fetal alcohol spectrum disorder in Canada


The assessment will help identify challenges and opportunities to strengthen Canada's approach to addressing FASD

OTTAWA, ON, Dec. 13, 2023 /CNW/ - Fetal alcohol spectrum disorder (FASD) is a lifelong disability caused by prenatal alcohol exposure that can affect both brain and body development.

FASD is a serious public health issue linked to many complex social determinants of health. It can have far reaching impacts on the lives of many Canadians and their families. Recent studies from Canada estimate that between 0.1% and 3% of children and youth have been diagnosed with FASD.

Today, the Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health announced close to $950,000 for the Canadian Academy of Health Sciences (CAHS) to undertake a comprehensive scientific assessment on FASD. The assessment will include a review of the relevant data, literature, policies, programs and practices, and engagement with key partners to identify challenges as well as opportunities to strengthen Canada's approach to addressing FASD and inform future priorities for action. It is anticipated that the assessment report will be finalized in 2024.

CAHS is a not-for-profit and fully independent organization that conducts research, engagement and undertakes evidenced-based assessments on a range of complex health and health-related issues of importance to Canadians.

Quotes

"We recognize the serious impacts FASD can have on individuals and families, with many facing mental health challenges and difficulties with substance use. We can better support Canadians affected by FASD by learning more and carefully examining the evidence and diverse perspectives around FASD prevention, awareness and support. Through this work, we aim to develop a more comprehensive approach to help prevent FASD and support the needs of people with FASD and their families."

The Honourable Ya'ara Saks
Minister of Mental Health and Addictions and Associate Minister of Health

"Addressing FASD in Canada will take a coordinated effort across federal departments, provincial and territorial governments, and with many different partners. This assessment will be key in strengthening this collaboration and building on lessons learned to ensure Canada has the proper tools in place to prevent FASD and to properly support people with this disorder, and their families."

The Honourable Mark Holland
Minister of Health

"We are pleased to be undertaking this important project that will inform stakeholders, governments, and indeed Canadians. We will also provide key findings on various aspects of FASD."

Dr. Marie-France Raynault
President of Canadian Academy of Health Sciences

Quick Facts
Associated Links

SOURCE Public Health Agency of Canada


These press releases may also interest you

10 mai 2024
On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system...

10 mai 2024
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

10 mai 2024
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

10 mai 2024
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

10 mai 2024
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

10 mai 2024
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...



News published on and distributed by: